Perioperative mezlocillin prophylaxis in cesarean section

Area of Science:

• Obstetrics and Gynecology
• Infectious Disease Prevention
• Surgical Prophylaxis

Background:

• Cesarean sections carry a risk of postoperative febrile morbidity and infection.
• Antibiotic prophylaxis is a standard measure to mitigate these risks.
• Evaluating specific antibiotics like mezlocillin is crucial for optimizing patient care.

Purpose of the Study:

• To prospectively evaluate the prophylactic efficacy of mezlocillin in preventing postoperative morbidity in women undergoing cesarean section.
• To compare the outcomes between patients receiving mezlocillin and those receiving a placebo.

Main Methods:

• A prospective study involving 113 patients undergoing cesarean section.
• Patients received either 2 gm of mezlocillin or a placebo intravenously.
• Dosing occurred 30 minutes before surgery and at 4 and 9 hours post-surgery.
• Outcomes assessed included febrile morbidity and specific postoperative infections.

Main Results:

• Overall postoperative morbidity was significantly reduced in the mezlocillin group (17%) compared to the placebo group (51%) (P < 0.01).
• This reduction in morbidity was significant only in patients who had begun labor before the cesarean section.
• No significant difference in morbidity reduction was observed in patients operated on before labor onset.

Conclusions:

• Mezlocillin demonstrates significant prophylactic efficacy in reducing postoperative morbidity following cesarean section.
• The benefit of mezlocillin prophylaxis is more pronounced in patients who have initiated labor prior to surgery.
• These findings support the targeted use of mezlocillin for specific cesarean section patient populations to enhance surgical outcomes.